Results 131 to 140 of about 34,967 (216)

Monitoring of Rivaroxaban Therapy in Hypercoagulable Dogs

Background Measurement of rivaroxaban efficacy using the rivaroxaban‐specific anti‐Xa assay (raXa) can be used for monitoring in veterinary medicine. Detection of rivaroxaban efficacy using other hemostatic tests would make monitoring timelier and more ...
R. Darren Wood, Anthony C. G. Abrams‐Ogg, Gabrielle Monteith, Shauna L. Blois, Erin M. Phillips, Benoît Cuq   +5 more
core   +1 more source

Direct Oral Anticoagulants Versus Vitamin K Antagonists for Treatment of Left Ventricular Thrombus: A Review of Efficacy and Safety. [PDF]

Rev Cardiovasc Med
Alqawasmi M, Alrahamneh O, Jawadi A, Blankenship JC.   +3 more
europepmc   +1 more source

The use of direct oral anticoagulants in children with congenital and acquired heart disease. [PDF]

Front Cardiovasc Med
Abdelghani E, Thakkar M, Berthiaume J, Ahuja S.   +3 more
europepmc   +1 more source

Pharmacogenomics of Rivaroxaban: Association of <i>CYP3A4, CYP3A5, CYP2J2, ABCB1</i>, and <i>ABCG2</i> Variants with Bleeding and Thrombotic Outcomes in Real-World Clinical Practice. [PDF]

Pharmaceutics
Slišković AM, Trkulja V, Ganoci L, Božina T, Pašara V, Vrkić Kirhmajer M, Palić J, Strikić D, Narančić M, Sopek Merkaš I, Merćep I, Bulum J, Šimičević L.   +12 more
europepmc   +1 more source

A Systematic Review and Meta-Analysis on the Use of Rivaroxaban as Thromboprophylaxis Following Bariatric Surgery. [PDF]

Obes Surg
Catania S, Caruana C.
europepmc   +1 more source

Rivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK? [PDF]

Clin Kidney J
Meijers BKI, Mavrakanas TA.
europepmc   +1 more source

Heparin-calibrated anti-factor Xa activity as a surrogate marker for direct oral anticoagulant levels in acute stroke care: a large observational single-center study. [PDF]

Neurol Res Pract
Büchsel M, Lisko K, Gölz H, Bardutzky J, Wiendl H, Felipa SB, Lambeck J.   +6 more
europepmc   +1 more source

Ex Vivo Reversierung der Effekte von Rivaroxaban

, 2017
Hintergrund: Neue orale Antikoagulanzien (NOACs) können schwerwiegende Blutungen verursachen, welche die behandelnden Ärzte vor große Herausforderungen stellen.
Schenk, Bettina
core  

Safety and effectiveness of dabigatran vs rivaroxaban in nonvalvular atrial fibrillation patients at nutritional risk. [PDF]

Res Pract Thromb Haemost
Liu L, Liu H, Aa G, Yang J, Zhang Z, Yang T, Sun B, Zuo L, Qin H, Liu S, Sia CH, Sun P, Yang Q, Zhou X.   +13 more
europepmc   +1 more source

Correction to “The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis”

Portal Hypertension &Cirrhosis, Volume 5, Issue 3, Page 304-305, September 2026.
wiley   +1 more source